昂利康(002940.SZ):擬與海昶生物簽訂“HC008”項目的合作協議並共設合資公司
格隆匯6月29日丨昂利康(002940.SZ)公佈,經與海昶生物的討論、協商,公司於2021年6月28日召開的第三屆董事會第五次會議審議通過了《關於與浙江海昶生物醫藥技術有限公司簽訂合作協議並投資設立參股公司暨關聯交易的議案》,公司擬與海昶生物簽訂《關於“HC008”合作項目的合作協議》並共同投資設立合資公司,就“HC008”(“標的藥品”)的研發、註冊、生產、商業化,項目合作、項目費用及合資公司的成立、運營等協商達成一致。
擬設立的合資公司認繳出資總額為人民幣1億元,雙方均以自有資金出資,其中海昶生物持股65%,公司持股35%。
海昶生物系公司聯營企業,公司副總經理楊國棟在海昶生物擔任其董事,根據《深圳證券交易所股票上市規則》,公司與海昶生物的共同對外投資構成了關聯交易,此次關聯交易事項尚需提交公司股東大會審議,若該議案經公司股東大會審議通過,公司董事會授權董事長或經營管理層簽署上述《合作協議》並辦理合資公司設立的相關事宜。
此次擬與海昶生物簽訂合作協議並共同投資設立合資公司是基於公司與海昶生物在HC008產品(一款酰胺類局部麻醉藥的複雜注射劑仿製藥,尚處於研發階段)上的合作,是公司在複雜製劑合同生產(CMO)業務上的嘗試,有助於提升公司在藥品製造領域的競爭優勢,進而提升公司未來核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.